BBIO Stock Recent News
BBIO LATEST HEADLINES
BridgeBio announced positive phase 2 results for infigratinib in treating children with achondroplasia. The company now plans to move forward with a pivotal phase 3 study of the experimental drug.
There's potentially good news for the medical community and definitely positive news for investors of BridgeBio Pharma (NASDAQ: BBIO ) stock. Reportedly, BridgeBio Pharma published clinical results from a proposed treatment for a rare condition affecting children.
BridgeBio Pharma smashed Wall Street's expectations in a study of children with dwarfism, leading BBIO stock to break out in massive volume. The post BridgeBio Soars 64% And Breaks Out After Smashing Expectations In A Dwarfism Study appeared first on Investor's Business Daily.
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -1.16% and 84.72%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
BridgeBio has some very significant price catalysts arriving in 2023 promising substantial upside should they be positive. Most important is Phase 3 interim data from Part B of a pivotal study of Acoramidis - indicated for ATTR.
BridgeBio Pharma, Inc. has a lot of irons in the fire. Despite BridgeBio Pharma, Inc. getting approvals for two products, there's hardly any revenue.
- The conference will take place at the National Cancer Institute at Frederick, Maryland from October 17-19, 2022
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of 11.96% and 146.13%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
BridgeBio Pharma Inc (NASDAQ: BBIO) announced promising pharmacodynamic data from the first two participants dosed in CANaspire Phase 1/2 trial of BBP-812, gene therapy for Canavan disease. Canavan disease is an ultra-rare inherited disorder that damages the ability of nerve.
BBIO lost hugely after the December phase 3 flop. So, although its business model is very interesting, it is not de-risked.